Last reviewed · How we verify
NCT06858566: KALIGO+
Impact of the Kaligo Solution on Learning to Write in Children Aged 6 to 11 With Handwriting Disorders : KALIGO+
NA trial testing Kaligo + score in Writing Disorder in 15 participants. Currently enrolling.
24 February 2027
Quick facts
| Lead sponsor | Fondation Ildys |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 15 |
| Start date | 21 March 2025 |
| Primary completion | 24 February 2027 |
| Estimated completion | 24 February 2027 |
| Sites | 1 location across France |
Drugs / interventions tested
- Kaligo + score
Conditions studied
- Writing Disorder — all drugs for Writing Disorder →
Sponsor
Fondation Ildys
Who can join
Adults 6 to 11, any sex, with Writing Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Writing is a fundamental skill, crucial to a child's success at school and the development of independence. Around 30% of children present difficulties in learning to write, and for some of them (10%), these difficulties persist for a long time. Adapted learning can improve their handwriting. Initial studies into the use of new technologies (tablets, virtual reality headsets) have shown that they can help children learn to write. Attractive to children, these interfaces make it possible to apply new paradigms (e.g. enrichment of feedback \[sonification\], variation of writing media) that have proved effective, mainly with children with 'typical' development. The Kaligo+ solution is based on the latest scientific advances to offer an innovative approach to learning to write, particularly for children with significant difficulties in this area. This study proposes to test the benefits of the Kaligo+ solution on 15 children with writing difficulties. The main objective of this pilot study is to demonstrate improved writing performance following use of the Kaligo+ solution in children aged 6 to 11 with writing difficulties, using a Single Case Experimental Design (SCED) methodology.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06858566
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Fondation Ildys trials
Trials by the same sponsor.
- NCT06963151 — Association of a HABIT-ILE Course and a Home Programme on the Bimanual Performance of Children With Cerebral Palsy · NA · not yet recruiting
- NCT07040722 — Effects of the Use of an Immersive Virtual Reality Device on Handwriting in Children Aged 6 to 13 With Handwriting Diffi · NA · recruiting
- NCT07189039 — Studying Access to Healthcare for Children in the Child Welfare System: the Health of Protected Children · completed
- NCT06941597 — Comparison of Two Gait Re-training Modalities During a Cardiac Rehabilitation Stay: Benefit of Orienteering Walking · completed
- NCT05219201 — Effectiveness of Cryotherapy on the Fatigue of Patients With Multiple Sclerosis · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06858566 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fondation Ildys
- Last refreshed: 28 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06858566.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing